^
Association details:
| Biomarker: | PIK3CA E542K |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
Excerpt:
In an open-label, multicenter, investigator-initiated National Comprehensive Cancer Network (NCCN)-sponsored trial, patients with metastatic or advanced STS received pazopanib 800 mg and 2 mg of trametinib continuously for 28-day cycles....A partial response occurred in 2 (8%) of the evaluable patients (95% CI, 1.0–26.0), one with PIK3CA E542K-mutant embryonal rhabdomyosarcoma...One of the patients with sinonasal embryonal rhabdomyosarcoma achieved a partial response with 59% tumor size reduction...
DOI:
10.1158/1078-0432.CCR-17-0272
